BioSpace News Archive

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it is scheduled to participate virtually in the Imperial Capital 2020 Security Investor Conference on Thursday, December 3, 2020. Dr. James A. Hayward, chief executive officer, will present at 10:45 a.m. EST that day and host one-on-one meetings throughout the d

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences: Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 12:30 p.m. ET. Piper Sandler 32nd Annual Virtual Healthc

Ziopharm Oncology, Inc., issued a response to a report issued by Institutional Shareholder Services in connection with the consent solicitation initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals.

Binovi Technologies Corp., a leader is neuro-vision performance technology, announces that, subject to the approval of the TSX Venture Exchange, it intends to settle $214,088.70 in outstanding indebtedness to an arms-length party through the issuance of an aggregate of 1,223,364 common shares at a price of $ 0.175 per share.

Correction of the press release published November 27, 2020. The release contained incorrect dates within the financial table. This has been corrected in the release below.

The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chie

FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO ® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and

-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval supports company’s approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway -- -- People living with these rare genetic diseases of obesity struggle with insatiable hunger and excessive weight gain beginning at a young age --